Compugen (CGEN) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Compugen (CGEN) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 22.2% versus a loss of 31.4%. Over five years, CGEN leads with a -66.2% price change compared with -94.8% for RNAC. Compugen is the larger company by market cap ($203.7 million vs $202.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEN | RNAC |
|---|---|---|
| Share price | $2.15 | $6.68 |
| Market cap | $203.66M | $202.11M |
| 1-day change | -3.15% | -1.04% |
| YTD return | +40.52% | -7.35% |
| 1-year return | +22.16% | -31.42% |
| 5-year return | -66.19% | -94.79% |
| P/E ratio (TTM) | 5.66 | — |
| EPS (TTM) | $0.38 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.24 | $11.00 |
| 52-week low | $1.43 | $5.60 |
| Distance from 52-week high | -33.64% | -39.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +113.95% | +404.04% |
| Average volume | 247.77K | 132.71K |
| Shares outstanding | 94.72M | 30.26M |
| Employees | 75 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEN has outperformed RNAC by 53.6 percentage points over the past year.
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Healthcare · Biotechnology · 75 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Healthcare · Biotechnology · 75 employees
CGEN vs RNAC FAQ
Which is bigger, Compugen or Cartesian Therapeutics?
Compugen (CGEN) is larger, with a market capitalization of $203.66M compared with $202.11M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, CGEN or RNAC?
CGEN returned +22.16% over the past 12 months, compared with -31.42% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Compugen and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.